Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Prepaid research and development current. Accrued research and development expense. Accrued liabilities and other liabilities current. Contractual obligation to collaborator, noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Restricted cash (SRX Cardio) Restricted Cash And Cash Equivalents At Carrying Value Prepaid research and development Prepaid Research And Development Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Intangible asset Intangible Assets Net Including Goodwill Prepaid and other long-term assets Prepaid Expense And Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued compensation and employee benefits Employee Related Liabilities Current Accrued research and development Accrued Research And Development Expense Accrued and other liabilities Accrued Liabilities And Other Liabilities Current Deferred revenue, current portion Deferred Revenue Current Total current liabilities Liabilities Current Notes payable, long-term Long Term Notes Payable Long term debt Long Term Debt Noncurrent Long term obligation to Collaborator Contractual Obligation To Collaborator Noncurrent Deferred revenue, long-term Deferred Revenue Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock Value Common stock, $0.001 par value, 100,000,000 shares authorized at March 31, 2017 and December 31, 2016; 57,009,237 and 56,544,218 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive income/(loss) Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders’ equity Stockholders Equity Noncontrolling interest (SRX Cardio) Minority Interest Total stockholders' equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Collaboration and license revenue License And Services Revenue Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest and other income, net Nonoperating Income Expense Interest expense Interest Expense Net loss Profit Loss Net loss attributable to noncontrolling interest (SRX Cardio) Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to Portola Net Income Loss Net loss per share attributable to Portola common stockholders: Earnings Per Share [Abstract] Basic and diluted Earnings Per Share Basic And Diluted Shares used to compute net loss per share attributable to Portola common stockholders: Weighted Average Number Of Shares Outstanding [Abstract] Basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Comprehensive loss attributable to noncontrolling interest (SRX Cardio) Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest Total comprehensive loss attributable to Portola Comprehensive Income Net Of Tax Non cash interest. Increase decrease in prepaid research and development. Increase decrease in prepaid expense and other current assets. Increase decrease in accrued research and development. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Amortization of premium on investment securities Investment Income Amortization Of Premium Non-cash interest expense Non Cash Interest Stock-based compensation expense Share Based Compensation Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid research and development Increase Decrease In Prepaid Research And Development Prepaid expenses and other current assets Increase Decrease In Prepaid Expense And Other Current Assets Prepaid and other long-term assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued compensation and employee benefits Increase Decrease In Employee Related Liabilities Accrued research and development Increase Decrease In Accrued Research And Development Accrued and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Deferred revenue Increase Decrease In Deferred Revenue Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Decrease in restricted cash (SRX Cardio) Increase Decrease In Restricted Cash Purchases of investments Payments To Acquire Investments Proceeds from maturities of investments Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from debt issuance, net Proceeds From Debt Net Of Issuance Costs Payment of public offering cost Payments Of Stock Issuance Costs Debt issuance costs paid Payments Of Debt Issuance Costs Proceeds from issuance of common stock pursuant to equity award plans Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net (decrease) increase in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization Nature Of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Purchase Commitments Commitments Disclosure [Text Block] Asset acquisition and license agreements. Research And Development [Abstract] Asset Acquisition and License Agreements Asset Acquisition Disclosure [Text Block] Debt Disclosure [Abstract] Long-term Debt Long Term Debt [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Net Loss per Share Attributable to Portola Common Stockholders Earnings Per Share [Text Block] Consolidation and Basis of Presentation Consolidation Policy [Text Block] Reclassification Prior Period Reclassification Adjustment Description Use of Estimates Use Of Estimates Variable Interest Entities Consolidation Variable Interest Entity Policy In-process Research and Development Asset In Process Research And Development Policy Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Investments in Marketable Securities Marketable Securities Policy Collaboration Customer Concentration Concentration Risk Credit Risk Revenue Recognition Revenue Recognition Policy [Text Block] Net Loss per Share Attributable to Portola Common Stockholders Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Percentage of Revenue from Significant Collaboration Customers Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block] Fair Value of Financial Assets and Liabilities Measured on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Cash Equivalents and Investments Classified as Available-for-sale Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Revenue from Collaboration and License Agreements Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Activity Table [Text Block] Schedule of share based compensation performance stock option awards activity. Summary of PSO Activity Schedule Of Share Based Compensation Performance Stock Option Awards Activity Table [Text Block] Summary of RSU Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Schedule of share based compensation performance stock units award activity. Summary of PSU Activity Schedule Of Share Based Compensation Performance Stock Units Award Activity Table [Text Block] Classification of Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Common Stock Equivalent Shares Excluded from Computation of Diluted Net Loss Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Number of operating segment Number Of Operating Segments Risks And Uncertainties [Abstract] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue Net [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Daiichi Sankyo Inc. Daiichi Sankyo, Inc ("Daiichi") Daiichi Sankyo Inc [Member] Bayer Pharma, AG and Janssen Pharmaceuticals, Inc. Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Bayer Pharma A G And Janssen Pharmaceuticals Inc [Member] Bristol Myers Squibb Company and Pfizer Inc. Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Bristol Myers Squibb Company And Pfizer Inc [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk percentage Concentration Risk Percentage1 New accounting pronouncement or change in accounting principle cumulative effect of differed tax assets. Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] Accounting standards update 201609. ASU No. 2016-09 Accounting Standards Update201609 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Cumulative effect of differed tax assets New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Differed Tax Assets Fair value measurement inputs disclosure. Fair value measurement inputs disclosure. Fair Value Measurement Inputs Disclosure [Table] Fair Value Measurement Inputs Disclosure [Table] Fair Value, Hierarchy Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 Fair Value Inputs Level1 [Member] Fair Value, Inputs, Level 2 Fair Value Inputs Level2 [Member] Fair Value, Inputs, Level 3 Fair Value Inputs Level3 [Member] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Embedded derivative liabilities Derivative Financial Instruments Liabilities [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Money market funds Money Market Funds [Member] Commercial paper and corporate securities. Corporate notes and commercial paper Commercial Paper And Corporate Securities [Member] U.S. government agency securities U S Government Agencies Debt Securities [Member] Fair Value Measurement Inputs Disclosure [Line Items] Fair Value Measurement Inputs Disclosure [Line Items] Financial Assets: Assets Fair Value Disclosure [Abstract] Total financial assets Assets Fair Value Disclosure Financial Liabilities: Liabilities Fair Value Disclosure [Abstract] Total financial liabilities Liabilities Fair Value Disclosure Fair value assets transfers from level 1 to level 2 Fair Value Assets Level1 To Level2 Transfers Amount Fair value assets transfers from level 2 to level 1 Fair Value Assets Level2 To Level1 Transfers Amount Fair value liabilities transfers from level 1 to level 2 Fair Value Liabilities Level1 To Level2 Transfers Amount Fair value liabilities transfers from level 2 to level 1 Fair Value Liabilities Level2 To Level1 Transfers Amount Fair value assets transfers into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Fair value assets transfers out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Fair value liabilities transfers into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Fair value liabilities transfers out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Cash equivalents Cash Equivalents [Member] Short-term investments Short Term Investments [Member] Long-term investments Other Long Term Investments [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Cost Available For Sale Securities Amortized Cost Unrealized Gains Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Unrealized (Losses) Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Estimated Fair Value Available For Sale Securities Available for sale securities maximum remaining contractual maturity. Available For Sale Securities Contractual Maturity Available For Sale Securities Maximum Remaining Contractual Maturity Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Collaborative arrangement with Bristol Myers Squibb Company And Pfizer Inc. Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Collaborative Arrangement With Bristol Myers Squibb Company And Pfizer Inc [Member] Collaborative arrangement with Daiichi Sankyo Inc. Daiichi Sankyo, Inc ("Daiichi") Collaborative Arrangement With Daiichi Sankyo Inc [Member] Collaborative arrangement with Bayer Pharma AG and Janssen Pharmaceuticals Inc. Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Collaborative Arrangement With Bayer Pharma A G And Janssen Pharmaceuticals Inc [Member] Collaborative arrangement with Bayer Pharma AG. Bayer Pharma AG Collaborative Arrangement With Bayer Pharma A G [Member] Collaborative arrangement with other companies. Other Collaborative Arrangement With Other Companies [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Milestone payments eligible for achievement. Revenue Recognition [Abstract] Report Date Creation Date [Axis] Financial Statement Filing Date Default Financial Statements Date [Member] Two thousand fourteen agreement. 2014 Agreement Two Thousand Fourteen Agreement [Member] Two thousand sixteen agreement. 2016 Agreement Two Thousand Sixteen Agreement [Member] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Milestone payments eligible for achievement Milestone Payments Eligible For Achievement Deferred revenue Deferred Revenue Payment receivable upon achievement of certain regulatory events. Payment receivable upon achievement of specified annual net sales volumes. Percentage of royalties entitle to receive under agreement. Payment receivable upon the achievement of certain regulatory events Payment Receivable Upon Achievement Of Certain Regulatory Events Payment receivable upon the achievement of annual net sales volumes Payment Receivable Upon Achievement Of Specified Annual Net Sales Volumes Percentage of royalties entitle to receive under agreement Percentage Of Royalties Entitle To Receive Under Agreement Milestone payments of regulatory clinical event and patient enrollment targets. Consideration of contingent and non contingent collaboration revenue to be recognized. Milestone payments of regulatory clinical event and patient enrollment targets Milestone Payments Of Regulatory Clinical Event And Patient Enrollment Targets Contingent and non-contingent consideration to be recognized after resolution of contingency Consideration Of Contingent And Non Contingent Collaboration Revenue To Be Recognized Milestone payments eligible for achievement of initial and final regulatory approval. Milestone payments eligible for achievement of initial and final regulatory approval Milestone Payments Eligible For Achievement Of Initial And Final Regulatory Approval Milestone payments eligible for achievement of certain events. Milestone payments eligible for achievement of certain events Milestone Payments Eligible For Achievement Of Certain Events Milestone payment associated with regulatory approval. Milestone payment associated with regulatory approval Milestone Payment Associated With Regulatory Approval Number of batches to be manufactured due within one year. Non refundable manufacturing reservation payments committed. Number of batches to be manufactured due in second year. Long Term Purchase Commitment [Table] Long Term Purchase Commitment [Table] Category of Item Purchased Long Term Purchase Commitment By Category Of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased Long Term Purchase Commitment Category Of Item Purchased [Domain] CMC ICOS Biologics Inc. CMC ICOS Biologics Inc C M C I C O S Biologics Inc [Member] Hovione Ltd. Hovione, Limited Hovione Ltd [Member] Long Term Purchase Commitment [Line Items] Long Term Purchase Commitment [Line Items] Number of batches to be manufactured, 2017 Number Of Batches To Be Manufactured Due Within One Year Non-refundable manufacturing reservation payments committed Non Refundable Manufacturing Reservation Payments Committed Purchase commitment, description Significant Purchase Commitment Description Number of batches to be manufactured, 2018 Number Of Batches To Be Manufactured Due In Second Year Purchase obligation services received. Repayment of accounts payable and accrued liabilities. Purchase obligation services received Purchase Obligation Services Received Repayment of accounts payable and accrued liabilities Repayment Of Accounts Payable And Accrued Liabilities Prepaid manufacturing services. Accounts payables Prepaid manufacturing services Prepaid Manufacturing Services Long-term purchase commitment, additional amount cancellable upon notice. Cancellable additional purchase commitments Long Term Purchase Commitment Additional Amount Cancellable Upon Notice Asset acquisition. Asset acquisition. Asset Acquisition [Table] Asset Acquisition [Table] Variable Interest Entities Variable Interest Entities By Classification Of Entity [Axis] Variable Interest Entity, Classification Classification Of Variable Interest Entity [Domain] SRX Cardio’ LLC. SRX Cardio S R X Cardio L L C [Member] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Variable interest entity, Terms of arrangements Variable Interest Entity Terms Of Arrangements Net loss attributable to Non Controlling interest (SRX Cardio) Number of debt instruments. Debt instruments maturity period. Debt Instrument [Table] Debt Instrument [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Promissory notes. Promissory Notes Promissory Notes [Member] Japan license agreement Member. Japan License Agreement Japan License Agreement [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States and European Units. United States and European Union United States And European Units [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Andexanet Alfa license agreement with all countries excluding Japan. Andexanet Alfa License Agreement with All Countries Excluding Japan Andexanet Alfa License Agreement With All Countries Excluding Japan [Member] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Axis] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Domain] Paid by December 31, 2021 Debt Instrument Redemption Period One [Member] Paid by December 31, 2023 Debt Instrument Redemption Period Two [Member] Purchase and sales agreement with HealthCare Royalty Partners and its affiliates. HealthCare Royalty Partners and its Affiliates (“HCR”) Purchase And Sales Agreement With Health Care Royalty Partners And Its Affiliates [Member] Products and Services Product Or Service [Axis] Products and Services Products And Services [Domain] Andexanet alfa. Andexanet Alfa Andexanet Alfa [Member] Scenario Statement Scenario [Axis] Scenario, Unspecified Scenario Unspecified [Domain] Scenario one. Scenario One Scenario One [Member] Scenario two. Scenario Two Scenario Two [Member] Scenario three. Scenario Three Scenario Three [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Proceeds from notes payable Proceeds From Notes Payable Number of debt instruments Number Of Debt Instruments Promissory notes, face amount Debt Instrument Face Amount Promissory notes due date Debt Instruments Maturity Period Debt instrument, payment of sales revenue by quarter, percent. Percentage of payments due to Company if initial regulatory approval not achieved. Percentage of license fees and milestone payments converted to notes payable if initial regulatory approval not achieved. Initial regulatory approval date. Debt instrument repayment terms. Percentage of net sales to be paid in each quarter Debt Instrument Payment Of Sales Revenue By Quarter Percent Percentage of payment receivable upon initial regulatory approval not achieved Percentage Of Payments Due To Company If Initial Regulatory Approval Not Achieved Percentage of license fees and milestone payments converted to notes payable upon initial regulatory approval not achieved Percentage Of License Fees And Milestone Payments Converted To Notes Payable If Initial Regulatory Approval Not Achieved Debt instrument repayment terms, description Debt Instrument Repayment Terms Initial regulatory approval date Initial Regulatory Approval Date Repayment amount Debt Instrument Repurchase Amount Repayment date Debt Instrument Repurchase Date Notes payable, accrued interest Interest Payable Current And Noncurrent Carrying value of notes payable Embedded derivative liabilities Embedded Derivative Fair Value Of Embedded Derivative Liability Estimated fair value of notes payable Notes Payable Fair Value Disclosure Proceeds from royalty sales agreement. Royalty interest additional amount receivable upon regulatory approval. Amount received under royalty sales agreement Proceeds From Royalty Sales Agreement Additional amount receivable upon U.S. regulatory approval Royalty Interest Additional Amount Receivable Upon Regulatory Approval Percentage of royalty obligated to pay under agreement. Target payment for royalty obligation. Percentage of royalty obligated to pay of net worldwide sales Percentage Of Royalty Obligated To Pay Under Agreement Target payment for royalty obligation Target Payment For Royalty Obligation Effective interest rate Debt Instrument Interest Rate Effective Percentage Additional debt issuance costs. Royalty sales agreement fee Royalty Expense Additional debt issuance costs Additional Debt Issuance Costs Interest expense, including amortization of debt discount Interest Expense Debt Long-term debt Payment-in-kind interest expense Paid In Kind Interest Outstanding debt, net of unamortized debt discount Debt Instrument Unamortized Discount Estimated fair value of long-term debt Long Term Debt Fair Value Share based compensation arrangement by share based payment award increase in shares available for issuance percentage of total common stock outstanding. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Performance stock option awards. Performance Stock Options (PSOs) Performance Stock Option Awards [Member] Performance Stock Units (PSUs) Performance Shares [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage increase in number of common stock outstanding Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Available For Issuance Percentage Of Common Stock Outstanding Common stock reserved, shares Common Stock Capital Shares Reserved For Future Issuance Employee Stock Option Employee Stock Option [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Twenty thirteen Equity Incentive Plan. 2013 Equity Incentive Plan Twenty Thirteen Equity Incentive Plan [Member] Shares Subject to Outstanding Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Options exercised Stock Issued During Period Shares Stock Options Exercised Options canceled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Ending balance Weighted-Average Exercise Price Per Share Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Options granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Options exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Options canceled Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Ending balance Unamortized share based compensation expected to be recognized over the remaining vesting period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unamortized share based compensation expected recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Share based compensation arrangement by share based payment award equity instruments other than options released in period. Restricted Stock Units (RSUs) Restricted Stock Units R S U [Member] Shares Subject to Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number RSUs granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period RSUs released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period RSUs canceled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending balance Share based compensation arrangement by share based payment award equity instruments other than options released in period weighted average grant date fair value. Weighted-Average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value RSUs granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value RSUs released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period Weighted Average Grant Date Fair Value RSUs canceled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending balance Performance-based RSUs awarded based on achievement of development goals, available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] Selling, General and Administrative Selling General And Administrative Expenses [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Employee stock purchase plan Employee Stock [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Stock options to purchase common stock Performance stock options Common stock warrants Warrant [Member] Restricted stock units Performance stock units Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Common stock equivalents excluded from computation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount